• In late February 2026, Eli Lilly reported a series of product updates, including positive EMA guidance for Olumiant in adolescents with severe alopecia areata, strong Phase 3 data for oral GLP-1 candidate orforglipron versus oral semaglutide, label expansion for Zepbound’s monthly KwikPen, and durable multi-year results for Omvoh in inflammatory bowel disease.
• These developments highlight how Lilly is broadening its cardiometabolic and immunology franchises beyond injectable GLP-1s, deepening its obesity and diabetes ecosystem while adding new, long-duration specialty therapies across dermatology and gastrointestinal disease.
• We’ll now examine how orforglipron’s positive head-to-head data against oral semaglutide may influence Eli Lilly’s obesity-focused investment narrative.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today, you have to believe its GLP-1 franchise can justify a premium valuation while the broader pipeline gradually reduces reliance on a few blockbusters. The latest batch of product updates largely reinforces that story rather than changing it, with orforglipron’s Phase 3 data still the key near term catalyst and payer pushback on obesity coverage remaining the most immediate risk.

The ACHIEVE-3 readout on orforglipron stands out as most relevant, because it directly addresses the upcoming competition in oral GLP-1s. Non inferiority to oral semaglutide over 52 weeks strengthens the case that an obesity indication, if approved, could extend Lilly’s cardiometabolic leadership. Combined with Zepbound’s KwikPen label expansion, these updates feed into the same core catalyst: how fully Lilly can convert its incretin science into durable, high volume prescription trends.

Yet despite all this momentum, investors should still weigh the risk that concentrated dependence on a few incretin products could...

Eli Lilly's narrative projects $89.1 billion revenue and $34.2 billion earnings by 2028.

Uncover how Eli Lilly's forecasts yield a $1211 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue near US$102.2 billion by 2028 and US$40.0 billion in earnings, while also warning that payer pushback like formulary exclusions could bite; this new orforglipron data could either reinforce those bullish views or prompt you to rethink how much risk you are willing to accept around pricing and access.

Explore 25 other fair value estimates on Eli Lilly - why the stock might be worth as much as 43% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Eli Lilly research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.